Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer (Q40303807)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2006

edit

Language	Label	Description	Also known as
English	Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer	scientific article published on March 2006

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

title

Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

main subject

biomarker

0 references

author name string

Yuji Bessho

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

Tetsuya Oguri

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

Hiroyuki Achiwa

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

Hideki Muramatsu

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

Hiroyoshi Maeda

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

Takashi Niimi

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

Shigeki Sato

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

Ryuzo Ueda

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

publication date

1 March 2006

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

published in

Cancer Science

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

volume

97

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

issue

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

page(s)

192-198

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

cites work

Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00164.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1349-7006.2006.00164.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

PubMed publication ID

16542215

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16542215

retrieved

19 September 2017

ResearchGate publication ID

7236938

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40303807&oldid=2173282024"